Clinical Characteristics and Treatment Outcomes for Patients Infected with<i>Mycobacterium haemophilum</i>
Pornboonya Nookeu, Nasikarn Angkasekwinai, Suporn Foongladda, Pakpoom Phoompoung
Emerging infectious diseases · 2019-07
Abstract
Mycobacterium haemophilum is a nontuberculous mycobacterium that can infect immunocompromised patients. Because of special conditions required for its culture, this bacterium is rarely reported and there are scarce data for long-term outcomes. We conducted a retrospective study at Siriraj Hospital, Bangkok, Thailand, during January 2012-September 2017. We studied 21 patients for which HIV infection was the most common concurrent condition. The most common organ involvement was skin and soft tissue (60%). Combination therapy with macrolides and fluoroquinolones resulted in a 60% cure rate for cutaneous infection; adding rifampin as a third drug for more severe cases resulted in modest (66%) cure rate. Efficacy of medical therapy in cutaneous, musculoskeletal, and ocular diseases was 80%, 50%, and 50%, respectively. All patients with central nervous system involvement showed treatment failures. Infections with M. haemophilum in HIV-infected patients were more likely to have central nervous system involvement and tended to have disseminated infections and less favorable outcomes.
MeSH terms
- Medicine
- Nontuberculous mycobacteria
- Internal medicine
- Retrospective cohort study
- Mycobacterium
- Human immunodeficiency virus (HIV)
- Surgery
- Dermatology